Literature DB >> 28448896

Differentially methylated embryonal Fyn-associated substrate (EFS) gene as a blood-specific epigenetic marker and its potential application in forensic casework.

Athina Vidaki1, Cecilia Johansson2, Federica Giangasparo2.   

Abstract

DNA methylation patterns have the ability to reveal the activities of genes within a certain tissue at a particular time point. Tissue-specific DNA methylation patterns have been previously investigated for their applicability in the identification of forensically relevant body fluids, however there is still a lack in robust markers. While following a genome-wide scale investigation has a great potential to reveal useful tissue-specific changes, a gene-targeted approach can also lead to significant outcomes, especially in genomic locations not included in the genome-wide experiments. In this study, the potential of the candidate embryonal Fyn-associated substrate (EFS) gene for the positive identification of whole blood was investigated. For this purpose, the methylation profile of a selected genomic region containing a total of 10 CpG sites was analysed in 124 individuals via bisulfite pyrosequencing. Volunteers donated various forensically relevant tissues, including whole blood, saliva, seminal fluid, vaginal fluid and menstrual secretion. Whole blood showed the highest levels of DNA methylation (mean=0.67), while semen samples were found to be very low methylated (mean=0.06). The remaining tissues demonstrated partial mean methylation levels; more specifically, saliva - 0.43, vaginal fluid - 0.22 and menstrual blood - 0.22. One out of the 10 analysed CpG sites, CpG4, showed to be more robust, resulting in not only the highest methylation difference between blood and the rest of the tissues, but also the lowest inter-individual methylation difference. The proposed pyrosequencing assay was found to be accurate, linear and reproducible. Lastly, the method's applicability to forensic casework was assessed via the analysis of very old bloodstains stored up to 18 years, blood DNA samples stored long-term up to 9 years, mixed stains as well as other 'forensic-like' samples. In the majority of cases the expected methylation ratios were obtained indicating a stable DNA methylation pattern, however caution is necessary when analysing low quantity and/or quality samples due to potential stochastic effects. Future validation experiments can shed more light into the usefulness of EFS locus as a promising blood-specific epigenetic marker.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bisulfite pyrosequencing; DNA methylation; EFS gene; Epigenetics; Forensic tissue identification blood

Mesh:

Substances:

Year:  2017        PMID: 28448896     DOI: 10.1016/j.fsigen.2017.04.010

Source DB:  PubMed          Journal:  Forensic Sci Int Genet        ISSN: 1872-4973            Impact factor:   4.882


  3 in total

1.  Marker evaluation for differentiation of blood and menstrual fluid by methylation-sensitive SNaPshot analysis.

Authors:  Hannah Holtkötter; Kristina Schwender; Peter Wiegand; Heidi Pfeiffer; Marielle Vennemann
Journal:  Int J Legal Med       Date:  2018-01-25       Impact factor: 2.686

2.  From forensic epigenetics to forensic epigenomics: broadening DNA investigative intelligence.

Authors:  Athina Vidaki; Manfred Kayser
Journal:  Genome Biol       Date:  2017-12-21       Impact factor: 13.583

3.  Validated inference of smoking habits from blood with a finite DNA methylation marker set.

Authors:  Silvana C E Maas; Athina Vidaki; Rory Wilson; Alexander Teumer; Fan Liu; Joyce B J van Meurs; André G Uitterlinden; Dorret I Boomsma; Eco J C de Geus; Gonneke Willemsen; Jenny van Dongen; Carla J H van der Kallen; P Eline Slagboom; Marian Beekman; Diana van Heemst; Leonard H van den Berg; Liesbeth Duijts; Vincent W V Jaddoe; Karl-Heinz Ladwig; Sonja Kunze; Annette Peters; M Arfan Ikram; Hans J Grabe; Janine F Felix; Melanie Waldenberger; Oscar H Franco; Mohsen Ghanbari; Manfred Kayser
Journal:  Eur J Epidemiol       Date:  2019-09-07       Impact factor: 8.082

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.